Edition:
United States

Impax Laboratories Inc (IPXL.OQ)

IPXL.OQ on NASDAQ Stock Exchange Global Select Market

16.95USD
22 Nov 2017
Change (% chg)

$0.10 (+0.59%)
Prev Close
$16.85
Open
$16.85
Day's High
$17.20
Day's Low
$16.77
Volume
84,127
Avg. Vol
380,735
52-wk High
$25.70
52-wk Low
$7.80

Latest Key Developments (Source: Significant Developments)

Impax Laboratories says co entered into amendment no. 1 to business combination agreement with Atlas Holdings ​
Tuesday, 21 Nov 2017 05:22pm EST 

Nov 21 (Reuters) - Impax Laboratories Inc :Impax Laboratories Inc - ‍on Nov 21, co entered into amendment no. 1 to business combination agreement, dated October 17, 2017 with Atlas Holdings ​.Impax Laboratories Inc - ‍also entered into amendment no. 1 with K2 Merger Sub Corporation & Amneal Pharmaceuticals Llc​.Impax Laboratories Inc - ‍in connection with closing, Holdco will be renamed Amneal Pharmaceuticals, Inc.​.Impax Laboratories - ‍in connection with pipe transaction, amneal desires to revise capital structure of new amneal to provide for class B-1 stock​.  Full Article

Impax Q3 adjusted earnings per share $0.23
Thursday, 9 Nov 2017 07:00am EST 

Nov 9 (Reuters) - Impax Laboratories Inc :Impax reports third quarter 2017 results.Q3 adjusted earnings per share $0.23.Q3 GAAP loss per share $0.69.Q3 earnings per share view $0.20 -- Thomson Reuters I/B/E/S.Q3 revenue $206.4 million versus I/B/E/S view $208.4 million.Impax Laboratories Inc - sees ‍2017 adjusted gross margins as a percent of total revenue are expected to be approximately 47%​.Impax Laboratories Inc - sees ‍full year 2017 adjusted net income per share of $0.60 to $0.65​.FY2017 earnings per share view $0.70 -- Thomson Reuters I/B/E/S.Impax Laboratories Inc - sees 2017 ‍capital expenditures of approximately $25 million to $30 million​.Impax Laboratories Inc - ‍company narrows full year 2017 guidance​.Impax Laboratories Inc - ‍"while our Q3 results were in line with our expectations, we continue to navigate challenging generic market environment"​.Impax Laboratories Inc - ‍currently expect to complete closure of our Middlesex, New Jersey packaging facility by end of 2017, ahead of schedule​.Impax Laboratories Inc - ‍"we are in late-stage negotiations for sale of our Taiwan manufacturing facility​".Impax Laboratories - ‍if successful in selling Taiwan facility by end of Q1 of 2018, co could realize anticipated cost savings by end of 2018​.  Full Article

Impax gets FDA approval for generic Renvela tablets
Monday, 23 Oct 2017 04:01pm EDT 

Oct 23 (Reuters) - Impax Laboratories Inc :Impax announces FDA approval and launch of generic Renvela (sevelamer carbonate) tablets, 800 mg.Impax Laboratories Inc - ‍impax has immediately initiated commercialization activities for a generic version of Renvela​.Impax Laboratories Inc - ‍sales of generic renvela are expected to benefit company's financial results this year​.  Full Article

IMPAX TO PAY AMNEAL $45 MLN IF DEAL TERMINATED UNDER CERTAIN CIRCUMSTANCES‍​
Tuesday, 17 Oct 2017 10:15am EDT 

Oct 17 (Reuters) - Impax Laboratories Inc ::REQUIRED TO PAY AMNEAL FEE OF $45 MILLION IF DEAL TERMINATED UNDER CERTAIN CIRCUMSTANCES‍​.AMNEAL TO BE ENTITLED TO REIMBURSEMENT FOR UP TO $15 MILLION EXPENSES, IF DEAL TERMINATED UNDER CERTAIN CIRCUMSTANCES - SEC FILING.  Full Article

Drugmaker Amneal to combine with Impax Labs
Tuesday, 17 Oct 2017 07:30am EDT 

Oct 17 (Reuters) - Impax Laboratories Inc :Amneal and Impax to combine.Transaction expected to generate $200 million of annual cost savings within three years​.Deal to be accretive to Impax's adjusted EPS within first 12 months​.Impax affirms 2017 financial guidance​.Amneal Holdings members to own about 75%, Impax shareholders to own about 25% of new co's pro forma shares on as converted basis​.Fy2017 earnings per share view $0.70, revenue view $800.8 million -- Thomson Reuters I/B/E/S.Combined company is expected to have 2018 pro forma adjusted EBITDA of approximately $700 million to $750 million​.Amneal's founders and co-chief executive officers, Chirag Patel & Chintu Patel, will serve as co-chairmen of combined co's board.‍Paul Bisaro, president and CEO of Impax, will serve as chief executive officer of combined company​.Co and ‍amneal Pharmaceuticals entered into a definitive business combination in an all-stock transaction​.Under terms of agreement, a new, publicly traded holding company, Amneal Pharmaceuticals Inc, will be formed​.Amneal Holdings members immediately prior to closing of transaction will receive non-economic, voting shares of Amneal Pharmaceuticals Inc​.Amneal Holdings members to be able to exchange membership units in Amneal Pharmaceuticals LLC for class A shares of Amneal Pharmaceuticals Inc​.Deal will be structured as "Up-C" deal with tax receivable agreement split 85% / 15% between Amneal Holdings members, Amneal Pharmaceuticals.  Full Article

Teligent announces FDA approval of partnered ANDA for Desonide Lotion
Monday, 2 Oct 2017 01:38pm EDT 

Oct 2 (Reuters) - Teligent Inc ::Teligent Inc announces FDA approval of partnered ANDA for Desonide Lotion, 0.05 pct.Says Desonide Lotion was submitted under a partnered development agreement by Teligent Inc With Impax Laboratories Inc​.Says currently plan to launch Desonide Lotion in Q4 of 2017.  Full Article

Impax Laboratories Q2 GAAP loss per share $0.28
Wednesday, 9 Aug 2017 07:00am EDT 

Aug 9 (Reuters) - Impax Laboratories Inc :Impax reports solid second quarter 2017 results with total revenues increasing 17% to $202 million.Q2 adjusted earnings per share $0.18.Q2 GAAP loss per share $0.28.Q2 revenue $202.1 million versus I/B/E/S view $195.6 million.Q2 earnings per share view $0.14 -- Thomson Reuters I/B/E/S.Reaffirms full year 2017 EPS guidance​‍.2017 adjusted gross margins as a percent of total revenue are expected to be approximately 47% to 49%​.Sees 2017 ‍capital expenditures of approximately $25 million to $30 million​.Sees ‍full year 2017 adjusted net income per share of $0.55 to $0.70​.FY2017 earnings per share view $0.66 -- Thomson Reuters I/B/E/S.  Full Article

Impax announces settlement of contract litigation on Opana ER CII extended-release tablets
Monday, 7 Aug 2017 07:30am EDT 

Aug 7 (Reuters) - Impax Laboratories Inc :Impax announces settlement of contract litigation on Opana ER (oxymorphone hydrochloride) CII extended-release tablets.Impax Laboratories - ‍announced settlement agreement to resolvea contract dispute relating to agreement entered into in June 2010 among endo international.Impax - co to pay Endo royalty rate that splits co's gross profits for sales of oxymorphone hydrochloride CII ER products, starting January 1, 2018​.Impax Laboratories Inc - ‍orange Book listed patents for Opana ER extend until November 2029.​.Impax Laboratories Inc - ‍further terms of settlement were not disclosed.​.  Full Article

Durect says ‍on July 24, Impax Laboratories terminated asset transfer and license agreement dated Jan. 3, 2014​
Friday, 28 Jul 2017 04:25pm EDT 

July 28 (Reuters) - Durect Corp :Durect - ‍on July 24, Impax Laboratories provided notice to co, that Impax is terminating asset transfer and license agreement dated January 3, 2014​.Durect Corp - termination returns to durect development and commercialization rights to Eladur(transdur)-bupivacaine) - SEC filing.  Full Article

Impax reports FDA approval of its AB rated generic concerta extended-release tablets CII
Monday, 17 Jul 2017 07:30am EDT 

July 17 (Reuters) - Impax Laboratories Inc ::Impax announces FDA approval of its AB rated generic concerta® (methylphenidate hydrochloride) extended-release tablets CII.Says don't anticipate sales of generic concerta to meaningfully impact earnings in 2017​.Says ‍preparing for launch including working to secure api quota and currently expect to launch by end of this year​.  Full Article

BRIEF-Impax Laboratories says co entered into amendment no. 1 to business combination agreement with Atlas Holdings ​

* Impax Laboratories Inc - ‍on Nov 21, co entered into amendment no. 1 to business combination agreement, dated October 17, 2017 with Atlas Holdings ​